Speech-Language Pathologists in Lafayette, CO Accepting Medicare

45 Speech-Language Pathologists found. Showing 41 - 45

Laura Emlen, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1070 Milo Cir Unit B, Lafayette, CO 80026 Phone: 303-362-3280

Janine Randol Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1400 Dixon St, Lafayette, CO 80026 Phone: 303-665-7789

Nicolette R Selensky Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 400 W South Boulder Rd Ste 2500, Lafayette, CO 80026 Phone: 720-515-4487

Dr. Barbara Rende, PH.D. CCC Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2330 Sandpiper Dr, Lafayette, CO 80026 Phone: 720-955-6815

Kristina Pickett, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1665 Coal Creek Dr, Lafayette, CO 80026 Phone: 303-926-6434

News Archive

Vascular Quality Improvement Initiative expands SVS' focus on clinical outcomes

The Society for Vascular Surgery (SVS) announced a new quality initiative to improve the care of patients with vascular disease. The Vascular Quality Improvement Initiative includes a registry and regional study groups to analyze the data collected from the registry. The initiative expands SVS' focus on clinical outcomes and benchmarked reporting.

U-Systems announces significant upgrade for somo•v ABUS at RSNA 2009

U-Systems, Inc., the leader in developing automated breast ultrasound systems, announced a significant upgrade for its somo•v™ Automated Breast Ultrasound System (ABUS) here at the 95th Annual Meeting of the Radiology Society of North America.

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

Read more Medical News

› Verified 5 days ago

• 1
• 2
• 3(current)